Dr. Uri Weinberg currently serves as Novocure’s Chief Science Officer overseeing early-stage research and development as well as the design and development stages of all clinical trials. Since joining Novocure in 2008, he has held several positions throughout his tenure with the company. Dr. Weinberg managed Novocure’s first clinical trial in lung cancer as well as the EF-14 clinical trial in newly diagnosed glioblastoma and built the company’s global Clinical Operations team in Switzerland. Prior to becoming Chief Science Officer in March 2020, Dr. Weinberg most recently held the position of Vice President of Clinical Development where he was responsible for expanding research activities, strengthening global clinical collaboration and initiating new discovery programs. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.